Keith Valentine, a director at Alphatec Holdings, Inc. (NASDAQ:ATEC), has increased his stake in the medical technology company with the purchase of 35,000 shares of common stock. The transaction, executed on November 10, 2026, was valued at $242,550, with shares acquired at prices ranging from $6.92 to $6.94 per share.
Following the purchase, Mr. Valentine directly holds 299,283 shares of Alphatec Holdings common stock. The buy comes at a time when the company's shares are trading near their 52-week low of $6.81, having declined 67% year-to-date. According to InvestingPro analysis, ATEC appears undervalued at current levels, placing it among the platform's most undervalued stocks. The company maintains a market capitalization of $1.09 billion and has reported revenue growth of 15%.
The insider transaction follows Alphatec's third-quarter 2026 earnings report, which fell short of Wall Street's expectations. The company posted adjusted earnings of $0.09 per share, slightly below the forecast of $0.10, and revenue of $221.17 million, missing the anticipated $225.44 million. Despite the miss, Alphatec achieved 13% year-over-year revenue growth. However, the market reacted negatively to softer biologics sales and a reduced full-year outlook.
In response to the earnings and guidance, TD Cowen lowered its price target for Alphatec to $10, citing intensified biologics headwinds and a market slowdown. Similarly, Needham adjusted its price target to $12 due to the revenue miss and reduced financial guidance. Both firms maintained a Buy rating on the shares.
These developments highlight recent challenges faced by Alphatec Holdings, even as a director has chosen to increase his position. The purchase by Mr. Valentine may signal confidence in the company's prospects, though the article does not speculate on his motivations. The stock closed at $7.00, down $0.38 or 5.15%, and traded at $7.08 in after-hours activity, up $0.08 or 1.14%.
For deeper insights into ATEC's financial health and growth prospects, InvestingPro offers exclusive access to comprehensive Pro Research Reports covering this and 1,400+ other US equities, along with additional ProTips beyond the 9 currently available for Alphatec.